{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:58:58Z","timestamp":1785185938359,"version":"3.55.0"},"reference-count":63,"publisher":"American Chemical Society (ACS)","issue":"24","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Developing small-molecule colon-selective therapies for localized drug action is an attractive strategy in treating colonic diseases. Due to the lack of a reliable approach to understand human colon exposures, there have been few successful examples of clinically validated colon-targeted drugs. In this study, we aim to develop a physiologically based pharmacokinetic modeling approach that guides molecular design, formulation selection, and clinical trial design of small-molecule colon-selective therapies. We focus on the colon selectivity achieved through high hepatic extraction and modified release formulation, which are most likely to be predicted with confidence currently. With the established model, sensitivity analyses have identified compound and formulation design principles for achieving desirable colon-to-systemic selectivity. We have also demonstrated how the model can be used to guide first-in-human and late-stage clinical trials design. Overall, the established approach helps to facilitate rational drug design and clinical trial design for small-molecule colon-selective therapies.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c02469","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T06:50:20Z","timestamp":1764831020000},"page":"26348-26364","source":"Crossref","is-referenced-by-count":0,"title":["A Novel Colon PBPK\nModel: Navigating the Rational\nDrug Design for Small-Molecule Colon-Selective Therapies"],"prefix":"10.1021","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1825-2401","authenticated-orcid":true,"given":"Rui","family":"Li","sequence":"first","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipy","family":"Vasa","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Cambridge, Massachusetts, United States, 02139"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Roy","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , , ,","place":["Groton, Connecticut, United States, 06340"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Pfizer Inc. , , Remote in FL , , ,","place":["Cocoa, Florida, United States, 32926"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"issue":"4","key":"2026072715483009100_cit1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus Kinase Inhibitors\nin Inflammatory Bowel Diseases","volume":"83","author":"Nunez","year":"2023","journal-title":"Drugs"},{"issue":"5","key":"2026072715483009100_cit2","doi-asserted-by":"publisher","first-page":"e616","DOI":"10.1093\/oncolo\/oyae014","article-title":"Ocular\nEffects of MEK Inhibitor Therapy:\nLiterature Review, Clinical Presentation, and Best Practices for Mitigation","volume":"29","author":"Jeng-Miller","year":"2024","journal-title":"Oncologist"},{"key":"2026072715483009100_cit3","unstructured":"Ebner, D.; Bootsma, A.; Brault, A.; Calabrese, M.; Corbett, M.; Dressler, H.; Fennell, K.; Hegen, M.; Kung, D.; LaChapelle, E.; et al.; Development of colon-targeted\npan-SIK inhibitor PF-07899895 for the treatment of IBD.  ACS Fall 2025: Washington, D.C.\nUSA, 2025."},{"issue":"7","key":"2026072715483009100_cit4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.2174\/1568026611313070002","article-title":"Intestinal targeting of drugs: rational\ndesign approaches and challenges","volume":"13","author":"Filipski","year":"2013","journal-title":"Curr. Top.\nMed. Chem."},{"key":"2026072715483009100_cit5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jconrel.2022.12.029","article-title":"Colonic drug delivery:\nFormulating the next generation\nof colon-targeted therapeutics","volume":"353","author":"McCoubrey","year":"2023","journal-title":"J. Controlled\nRelease"},{"issue":"7","key":"2026072715483009100_cit6a","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/BF01299921","article-title":"Studies\nof two novel sulfasalazine\nanalogs, ipsalazide and balsalazide","volume":"28","author":"Chan","year":"1983","journal-title":"Dig. Dis.\nSci."},{"issue":"8044","key":"2026072715483009100_cit6b","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/s0140-6736(77)90831-5","article-title":"An experiment to\ndetermine the active therapeutic moiety of sulphasalazine","volume":"310","author":"Khan","year":"1977","journal-title":"Lancet"},{"issue":"1","key":"2026072715483009100_cit7a","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0378-5173(96)04592-9","article-title":"Compartmental\ntransit\nand dispersion model analysis of small intestinal transit flow in\nhumans","volume":"140","author":"Yu","year":"1996","journal-title":"Int. J. Pharm."},{"issue":"2","key":"2026072715483009100_cit7b","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0378-5173(99)00147-7","article-title":"A compartmental absorption and transit\nmodel for estimating oral drug absorption","volume":"186","author":"Yu","year":"1999","journal-title":"Int.\nJ. Pharm."},{"issue":"2","key":"2026072715483009100_cit8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0378-5173(98)00174-4","article-title":"Characterization\nof small intestinal transit time distribution\nin humans","volume":"171","author":"Yu","year":"1998","journal-title":"Int. J. Pharm."},{"issue":"Suppl 1","key":"2026072715483009100_cit9","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/s0169-409x(01)00179-x","article-title":"Predicting\nthe impact of physiological\nand biochemical processes on oral drug bioavailability","volume":"50","author":"Agoram","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"2026072715483009100_cit10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic\nprediction\nof oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J."},{"issue":"10","key":"2026072715483009100_cit11","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1111\/bcp.15786","article-title":"A phase\n1 study to investigate the absorption, distribution, metabolism and\nexcretion of brepocitinib in healthy males using a (14) C-microdose\napproach","volume":"89","author":"Qiu","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"15","key":"2026072715483009100_cit12","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.1021\/acs.jmedchem.5b00201","article-title":"Volume of Distribution\nin Drug Design","volume":"58","author":"Smith","year":"2015","journal-title":"J. Med. Chem."},{"issue":"5","key":"2026072715483009100_cit13","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1021\/acs.jmedchem.8b01263","article-title":"Clearance in Drug Design","volume":"62","author":"Smith","year":"2019","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026072715483009100_cit14","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1021\/acs.molpharmaceut.5b00861","article-title":"In Silico\nModeling of Gastrointestinal\nDrug Absorption: Predictive Performance of Three Physiologically Based\nAbsorption Models","volume":"13","author":"Sjogren","year":"2016","journal-title":"Mol. Pharmaceutics"},{"issue":"2","key":"2026072715483009100_cit15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1046\/j.1365-2036.2000.00697.x","article-title":"Limited\nexposure of the healthy distal colon to orally-dosed formulation is\nfurther exaggerated in active left-sided ulcerative colitis","volume":"14","author":"Hebden","year":"2000","journal-title":"Aliment Pharmacol. Ther."},{"key":"2026072715483009100_cit16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/9781118140291.app1","article-title":"Appendices","volume-title":"Physiologically-Based Pharmacokinetic\n(PBPK) Modeling\nand Simulations","author":"Peters","year":"2012"},{"issue":"1","key":"2026072715483009100_cit17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform\nPBPK model to characterize the plasma\nand tissue disposition of monoclonal antibodies in preclinical species\nand human","volume":"39","author":"Shah","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"5","key":"2026072715483009100_cit18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison\nof the gastrointestinal anatomy, physiology, and biochemistry of humans\nand commonly used laboratory animals","volume":"16","author":"Kararli","year":"1995","journal-title":"Biopharm.\nDrug Dispos."},{"issue":"6","key":"2026072715483009100_cit19","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3109\/00365521.2014.898326","article-title":"Surface area of the\ndigestive tract - revisited","volume":"49","author":"Helander","year":"2014","journal-title":"Scand J. Gastroenterol."},{"issue":"6","key":"2026072715483009100_cit20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1308\/003588415X14181254790527","article-title":"Segmental\ncolonic length and mobility","volume":"97","author":"Phillips","year":"2015","journal-title":"Ann. R. Coll. Surg.\nEngl."},{"issue":"2","key":"2026072715483009100_cit21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1208\/s12248-009-9087-2","article-title":"Role of\nphysiological intestinal water in oral absorption","volume":"11","author":"Sutton","year":"2009","journal-title":"AAPS J."},{"issue":"10","key":"2026072715483009100_cit22","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","article-title":"Intestinal\nfluid volumes and transit\nof dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment Pharmacol. Ther."},{"issue":"5","key":"2026072715483009100_cit23","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1208\/s12248-016-9953-7","article-title":"A Quantitative\nReview and Meta-models\nof the Variability and Factors Affecting Oral Drug Absorption-Part\nII: Gastrointestinal Transit Time","volume":"18","author":"Abuhelwa","year":"2016","journal-title":"AAPS J."},{"issue":"11","key":"2026072715483009100_cit24","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1002\/jps.22674","article-title":"Development of a new\npermeability assay using low-efflux MDCKII cells","volume":"100","author":"Di","year":"2011","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"2026072715483009100_cit25","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1021\/acs.jmedchem.5c00725","article-title":"Free Drug Concepts:\nA Lingering Problem in Drug Discovery","volume":"68","author":"Webborn","year":"2025","journal-title":"J. Med.\nChem."},{"issue":"6","key":"2026072715483009100_cit26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/17460441.2025.2491670","article-title":"Use of\npharmacokinetic versus pharmacodynamic endpoints\nto support human dose predictions: implications for rational drug\ndesign and early clinical development","volume":"20","author":"Li","year":"2025","journal-title":"Expert\nOpin. Drug Discovery"},{"issue":"6","key":"2026072715483009100_cit27","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/BF01060053","article-title":"Evaluation of methods for estimating\npopulation pharmacokinetics\nparameters. I. Michaelis-Menten model: routine clinical pharmacokinetic\ndata","volume":"8","author":"Sheiner","year":"1980","journal-title":"J. Pharmacokinet. Biopharm."},{"issue":"1","key":"2026072715483009100_cit28","doi-asserted-by":"publisher","first-page":"8974","DOI":"10.1038\/s41598-020-65762-y","article-title":"Demonstration\nof In Vitro to In Vivo Translation\nof a TYK2 Inhibitor That Shows Cross Species Potency Differences","volume":"10","author":"Gerstenberger","year":"2020","journal-title":"Sci. Rep."},{"key":"2026072715483009100_cit29a","doi-asserted-by":"publisher","first-page":"105242","DOI":"10.1016\/j.ejps.2020.105242","article-title":"Insight into the colonic disposition\nof celecoxib in humans","volume":"145","author":"Lemmens","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"2026072715483009100_cit29b","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/MIB.0000000000000597","article-title":"Assessing\nColonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel\nOral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative\nColitis","volume":"22","author":"Sands","year":"2016","journal-title":"Inflammatory Bowel Dis."},{"issue":"9","key":"2026072715483009100_cit29c","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1093\/ecco-jcc\/jjaa049","article-title":"Development of Gut-Selective\nPan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational\nMedicine Programme","volume":"14","author":"Sandborn","year":"2020","journal-title":"J. Crohns Colitis"},{"issue":"5","key":"2026072715483009100_cit30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1124\/dmd.116.074575","article-title":"Novel Method to Predict\nIn Vivo Liver-to-Plasma K(puu) for OATP Substrates\nUsing Suspension Hepatocytes","volume":"45","author":"Riccardi","year":"2017","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"2026072715483009100_cit31","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1021\/mp2004912","article-title":"pH-Dependent solubility and permeability criteria\nfor provisional biopharmaceutics classification (BCS and BDDCS) in\nearly drug discovery","volume":"9","author":"Varma","year":"2012","journal-title":"Mol. Pharmaceutics"},{"issue":"3","key":"2026072715483009100_cit32","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1517\/17425250902835506","article-title":"Introduction\nto computational oral absorption simulation","volume":"5","author":"Sugano","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"2026072715483009100_cit33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/9781119772729.ch19","article-title":"In Vitro\u2013In\nVivo Correlations for Modified Release Formulations","volume-title":"Oral Drug Delivery for Modified Release Formulations","author":"Tomic","year":"2022"},{"issue":"3","key":"2026072715483009100_cit34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1208\/s12248-023-00800-x","article-title":"In Vitro-In Vivo Extrapolation and Scaling Factors for Clearance\nof Human and Preclinical Species with Liver Microsomes and Hepatocytes","volume":"25","author":"Tess","year":"2023","journal-title":"AAPS J."},{"key":"2026072715483009100_cit35","doi-asserted-by":"publisher","first-page":"105200","DOI":"10.1016\/j.ejps.2019.105200","article-title":"Development\nand validation of a Level A in-vitro in-vivo correlation for tofacitinib\nmodified-release tablets using extrudable core system osmotic delivery\ntechnology","volume":"147","author":"Kushner","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"issue":"4","key":"2026072715483009100_cit36","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/cpt.3313","article-title":"Integrating Clinical\nVariability into PBPK Models for\nVirtual Bioequivalence of Single and Multiple Doses of Tofacitinib\nModified-Release Dosage Form","volume":"116","author":"Purohit","year":"2024","journal-title":"Clin. Pharmacol.\nTher."},{"key":"2026072715483009100_cit37a","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejpb.2023.03.013","article-title":"Physiologically based\nbiopharmaceutics modeling of regional and colon absorption in humans","volume":"186","author":"Tannergren","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"12","key":"2026072715483009100_cit37b","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.1002\/jps.22726","article-title":"Evolution of a detailed physiological\nmodel to simulate the gastrointestinal transit and absorption process\nin humans, part 1: oral solutions","volume":"100","author":"Thelen","year":"2011","journal-title":"J. Pharm.\nSci."},{"issue":"3","key":"2026072715483009100_cit37c","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/jps.22825","article-title":"Evolution of a detailed physiological\nmodel to simulate the gastrointestinal transit and absorption process\nin humans, part II: extension to describe performance of solid dosage\nforms","volume":"101","author":"Thelen","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"2026072715483009100_cit38a","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1124\/dmd.124.001750","article-title":"The Metabolism and Disposition of\nBrepocitinib in Humans and Characterization of the Formation Mechanism\nof an Aminopyridine Metabolite","volume":"52","author":"Dowty","year":"2024","journal-title":"Drug Metab.\nDispos."},{"issue":"4","key":"2026072715483009100_cit38b","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms\nof tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab. Dispos."},{"issue":"9","key":"2026072715483009100_cit39","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1124\/dmd.111.039248","article-title":"Physiologically based pharmacokinetic\nmodeling of intestinal first-pass metabolism of CYP3A substrates with\nhigh intestinal extraction","volume":"39","author":"Gertz","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"2026072715483009100_cit40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/psp4.13249","article-title":"PBPK modeling:\nWhat is the role of CYP3A4 expression in the gastrointestinal tract\nto accurately predict first-pass metabolism?","volume":"14","author":"Henriot","year":"2025","journal-title":"CPT:Pharmacometrics Syst. Pharmacol."},{"issue":"1","key":"2026072715483009100_cit41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0022-5320(81)80047-0","article-title":"Morphometric analysis of the membranes and organelles\nof small intestinal enterocytes. II. lipid-fed hamster","volume":"76","author":"Buschmann","year":"1981","journal-title":"J. Ultrastruct. Res."},{"issue":"10","key":"2026072715483009100_cit42","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/labinvest.3700464","article-title":"Characterization\nof epithelial cell shedding from human small intestine","volume":"86","author":"Bullen","year":"2006","journal-title":"Lab. Invest."},{"issue":"4","key":"2026072715483009100_cit43","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1242\/dev.110.4.1001","article-title":"Stem cells: attributes, cycles, spirals,\npitfalls and\nuncertainties. Lessons for and from the crypt","volume":"110","author":"Potten","year":"1990","journal-title":"Development"},{"issue":"3","key":"2026072715483009100_cit44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1046\/j.1365-2184.2003.00264.x","article-title":"The small intestine as a model for\nevaluating adult tissue stem cell drug targets","volume":"36","author":"Potten","year":"2003","journal-title":"Cell Proliferation"},{"issue":"2","key":"2026072715483009100_cit45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191997","article-title":"Atlas of the human\nintestine","volume":"217","author":"He","year":"2020","journal-title":"J. Exp. Med."},{"issue":"6","key":"2026072715483009100_cit46","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic\nmodelling 2:\npredicting the tissue distribution of acids, very weak bases, neutrals\nand zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"2026072715483009100_cit47","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/0016-5085(84)90190-2","article-title":"Intestinal transit\nof solid and liquid components of a meal in health","volume":"87","author":"Malagelada","year":"1984","journal-title":"Gastroenterology"},{"issue":"3","key":"2026072715483009100_cit48a","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00006231-199003000-00003","article-title":"Fractional gastrointestinal transit\ntime: intra- and interindividual variation","volume":"11","author":"Birkebaek","year":"1990","journal-title":"Nucl. Med. Commun."},{"issue":"10","key":"2026072715483009100_cit48b","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1007\/BF01296501","article-title":"Effects of gender, age, and body mass index on gastrointestinal\ntransit times","volume":"37","author":"Madsen","year":"1992","journal-title":"Dig. Dis. Sci."},{"issue":"2","key":"2026072715483009100_cit48c","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/gut.39.2.299","article-title":"Variability of gastrointestinal transit\nin healthy women and men","volume":"39","author":"Degen","year":"1996","journal-title":"Gut"},{"issue":"9","key":"2026072715483009100_cit49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/psp4.12445","article-title":"Nonlinear Mixed-Effects\nModel Development and Simulation Using nlmixr and Related R Open-Source\nPackages","volume":"8","author":"Fidler","year":"2019","journal-title":"CPT:Pharmacometrics Syst. Pharmacol."},{"issue":"1\u20132","key":"2026072715483009100_cit50","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ijpharm.2009.02.002","article-title":"Theoretical\ninvestigation of passive intestinal membrane permeability using Monte\nCarlo method to generate drug-like molecule population","volume":"373","author":"Sugano","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"10\u201311","key":"2026072715483009100_cit51","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/00498250701704819","article-title":"Intestinal\npermeability and its relevance for absorption and elimination","volume":"37","author":"Lennernas","year":"2007","journal-title":"Xenobiotica"},{"issue":"9","key":"2026072715483009100_cit52","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/jps.24258","article-title":"Direct In\nVivo Human Intestinal Permeability (Peff) Determined with Different\nClinical Perfusion and Intubation Methods","volume":"104","author":"Dahlgren","year":"2015","journal-title":"J.\nPharm. Sci."},{"issue":"5","key":"2026072715483009100_cit53","doi-asserted-by":"publisher","first-page":"G922","DOI":"10.1152\/ajpgi.2001.280.5.G922","article-title":"The adherent gastrointestinal\nmucus gel layer: thickness and physical state in vivo","volume":"280","author":"Atuma","year":"2001","journal-title":"Am. J. Physiol.: Gastrointest. Liver Physiol."},{"issue":"1","key":"2026072715483009100_cit54","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/psp4.12052","article-title":"A Tutorial\non RxODE: Simulating Differential\nEquation Pharmacometric Models in R","volume":"5","author":"Wang","year":"2016","journal-title":"CPT:Pharmacometrics\nSyst. Pharmacol."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c02469","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/24\/26348\/66290500\/acs.jmedchem.5c02469.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/24\/26348\/66290500\/acs.jmedchem.5c02469.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T20:04:31Z","timestamp":1785182671000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/24\/26348\/5234577\/A-Novel-Colon-PBPK-Model-Navigating-the-Rational"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":63,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12,4]]},"published-print":{"date-parts":[[2025,12,25]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02469","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]}}}